

FIG. 1




FIG. 2A

2/13




FIG. 2B




FIG. 2C




FIG. 3A

4/13





FIG. 3B



# FIG. 4A

5/13

## WT and Mutant Oligonucleotides of -164/-128, 5' $\beta$ -Globin

WT sequence: 5' AACTCCTAAGC CAGTGCCCAGAAGAGCCAAGGACAGGT 3'

Mutant #1 (-162/-157): 5' AAGGGGGGAGCCAGTGCCAGAAGAGCCAAGGACAGGT 3'

Mutant #2 (-144/-139): 5' AACTCCTAAGCCAGTGCCAG AAAAAACAAGGACAGGT 3'

Mutant #3 (-135/-130): 5' AACTCCTAAGCCAGTGCCAGAAGAGCCAA CCCCCCGT 3'

Mutant #4 (-153/-148): 5' AACTCCTAAGC AAAAAACAGAAGAGCCAAGGACAGGT 3'

# FIG. 4B




FIG. 4C

6/13




FIG. 4D

Competitor Oligonucleotide	Molar Excess producing 50 % Inhibition
Wild type (WT)	42x
Mutant #1	30x
Mutant #2	38x
Mutant #3	35x
Mutant #4	850x

[illegible][illegible]

FIG. 6







FIG. 7



1000369-110101

FIG. 8




FIG. 9




FIG. 10




FIG. 11





FIG. 12



699E000F